Berdagang BioNTech BNTX

Jual
 Beli

BioNTech carta live

5m 15m 30m 1h 4h 1d 1w

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

BioNTech news

Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Berita Terkini

Tunjukkan lebih lagi
Frances Wang 2025 Jun 25, 16:00

Stock Mover Today: Why BAC Stock Is Trending Now?

Stocks
Frances Wang 2025 Jun 25, 16:00

MSTR Stock News: MSTR Shares Rise 1.9% Amid Mixed Options Market Sentiment

Stocks
Ghko B 2025 Jun 25, 16:00

Stock indexes today: Dow Jumps 500 Points, S&P 500 Rises on Trump Ceasefire

Stocks
Frances Wang 2025 Jun 24, 16:00

Value of bitcoin today: BTC/USD over 106K as Middle East tensions eased

Cryptocurrencies
Frances Wang 2025 Jun 24, 16:00

Market movers today: Carnival, Tesla, Mastercard, SOFI

Stocks
Tommy Yap 2025 Jun 24, 16:00

Morning Note: Ceasefire Boosts Markets; Dovish Fed & RBA Rate Cut Bets Emerge

Morning Note Stocks Forex
Tommy Yap 2025 Jun 24, 16:00

Morning Note: Powell on Tariffs; Oil Rebounds; Aussie Inflation Cools

Morning Note Commodities Forex
Ghko B 2025 Jun 23, 16:00

IBO stock up 200% today: what’s going on with Impact Biomedical

Stocks

Maklumat

Sebaran nilai

1.2079

Spread (%)

1.1609 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran dibuka

Khamis

13:31 - 19:59

Isnin

13:31-19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Jumaat

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

25263110144

Saham Tertunggak

240395008

Tarikh Pendapatan (Seterusnya)

0000-00-00

Hasil Div

2022-06-17

Tarikh Selepas Dividen

2022-06-02

Kadar dividen tahunan depan

0

Hasil dividen tahunan depan

0

EPS

-3.67

Ketahui lebih lanjut mengenai instrumen ini

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Instrumen Berkaitan

Aset
Jual
Beli
Perubahan (%):

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang
Instrumen Berkaitan

latest_education_articles

Tunjukkan lebih lagi
Trustpilot